In the fourth quarter, the company’s revenue grew 10 percent to $6 billion. The sales growth was attributed to Bristol’s top-selling products, including its lung cancer drug Opdivo and blood thinner Eliquis, which saw sales rise 33 percent and 25 percent, respectively.
For fiscal year 2018, Bristol Myers reported a profit of $4.95 billion and sales of $22.6 billion.
The results exceeded Wall Street expectations.
More articles on pharmacy:
Bayer to shut down Pennsylvania plant, eliminate 600 jobs
New drug shortages rose 27% in 2018
FDA moves to fast-track OTC naloxone
